WO2017181977A1 - Mussel adhesive protein product and use thereof for inhibiting soft tissue inflammation - Google Patents

Abstract

Disclosed in the present invention is a use of a mussel adhesive protein or a preparation thereof for inhibiting soft tissue inflammation. Specifically disclosed is the use of the mussel adhesive protein or preparation thereof in the treatment of soft tissue inflammation and the like caused by contusion or laceration of muscle, ligament, fascia, tendon, synovial membrane, fat, joint capsule and lymphatic tissue. The mussel adhesive protein or preparation thereof can inhibit the redness, swelling, hotness, pain and other symptoms caused by soft tissue inflammation.

Description

Mussel mucin product and its application for inhibiting soft tissue inflammation

This application claims priority to the International Patent Application No. PCT/CN2016/079768, entitled "Mub Shell Mucin Product and Its Application for Inhibiting Soft Tissue Inflammation", filed on April 20, 2016, all of which is hereby incorporated by reference. The content is incorporated herein by reference.

Technical field

The present invention relates generally to the fields of pharmaceuticals, medical products, health care products, and food technology, and more particularly to mussel mucin products and their use in inhibiting inflammation of soft tissues.

Related technical discussion

Soft tissue refers to the subcutaneous tissue, muscle, tendon, ligament, joint capsule and other tissues of the human body. Soft tissue inflammation refers to a large class of microcirculatory disorders and aseptic inflammation caused by direct or indirect violence or long-term chronic strain of soft tissue. Causes of soft tissue inflammation include knives, falls, beatings, contusions, puncture wounds, abrasions, sports injuries, etc. The clinical manifestations are mainly swelling and pain. Local oozing, edema, and severe pain in the acute phase. In the late stage, muscle, tendon adhesion, ischemic contracture, inflammation around the joints, and even joint stiffness may occur. Soft tissue inflammation treatment usually chooses different methods according to different degrees. Mild inflammation often uses physical therapy such as cold compress, hot compress and massage. Severe inflammation is often treated with non-steroidal anti-inflammatory drugs. Such drugs include aspirin, acetaminophen, indomethacin, naproxen, naproxen, diclofenac, ibuprofen, nimesulide, rofecoxib, celecoxib, etc., mainly through inhibition The synthesis of prostaglandins exerts its anti-inflammatory, anti-rheumatic, analgesic, antipyretic and anticoagulant effects. Recently, the US Food and Drug Administration (FDA) believes that non-steroidal anti-inflammatory drugs have potential cardiovascular and gastrointestinal bleeding risks, and can cause adverse reactions such as gastrointestinal, liver, nervous system, and urinary system.

Mussel adhesive protein (MAP), also known as Mytilus edulis foot protein (Mefp), is a marine shellfish, Mytilus edulis Linnaeus, and a small shell mussel (Mytilus coruscus). A special protein secreted by Perna viridis. Mussels are usually attached in groups to the reefs on the coast or to the bottom of the ship, and have the ability to withstand wave impacts in the offshore. In fact, mussels can be attached extremely strongly to the substrate of any material, such as metal, wood, glass, and the like. The main reason for the above characteristics of mussels is that they can produce and store this special mucin in the girth of the foot, and the mussels are released through the foot. Mucin forms a water-resistant bond to a solid surface such as rock, thereby fixing itself.

Currently, 11 mucin subclasses have been identified from mussels, including mefp1, mefp-2, mefp-3, mefp-4, mefp-5, mefp-6, collagen pre-COL-P, pre-COL-D. , pre-COL-NG, foot silk matrix proteins PTMP and DTMP (Zhu Xi et al, Advances in Marine Science, 2014, 32(4): 560-568). Mussel mucin has two structural features: (1) containing lysine, which has a high loading of positive charge; (2) containing 3,4 dihydroxyphenylalanine (DOPA, dopa). The cells and tissues of the human body are negatively charged. Mussel mucin plays a protective and therapeutic role by tightly binding cells and tissues through the electrostatic interaction between its own positive charge and the negative charge of cells and tissues. In addition, dopa oxidation produces ortho-dioxins, which can be cross-linked with unoxidized dopa to form a membrane or a network scaffold, which promotes the protein to adhere more closely and firmly to the surface of the human body, thereby protecting. Mussel mucin is a macromolecular protein that is completely degraded in the human body for about 3-10 days. Its ability to attach to cell tissues is excellent, so that mussel mucin can be stabilized locally and continue to function.

Although mussel mucin has the above characteristics, its current application field is very limited. Commercial mussel mucin products are Cell-Tak from BD Biosciences, MAP Trix from Kollodis, Korea, and Hydrogel from Biopolymer, Sweden. These products are either used directly in the mussel mucin solution state, or are stored as lyophilized powder formulations and dissolved prior to use. Their primary application is limited to microscopic cell adhesion and tissue adhesives. Mussel mucin has also been reported for use in the repair of fetal membranes, as a coating against seawater corrosion, and as a drug-loaded stent for the heart.

Summary of the invention

It is an object of the present invention to provide a mussel mucin product.

Mussel mucin used herein refers to Mytilus edulis Linnaeus, Mytilus coruscus or Perna viridis from the Mytilidae bivalve mollusc. 11 subclasses of mussel mucin, currently known as purified from marine mussels: mefp1, mefp-2, mefp-3, mefp-4, mefp-5, mefp-6, collagen pre-COL- A mixture of one or more of P, pre-COL-D, pre-COL-NG, foot silk matrix proteins PTMP and DTMP. The mussel mucin used herein may have a pH of 1.0 to 7.0 in an aqueous solution, and particularly may be in the range of pH 3.0 to 6.5 to make the therapeutic effect better.

The mussel mucin used herein can be obtained by the following preparation methods, such as Chinese A method for separating and purifying mussel mucin using mixed adsorption chromatography, ZL200710179491.0, Chinese Patent No. ZL200710179492.5, a method for purifying mussel mucin using carboxymethyl ion exchange chromatography, Chinese Patent No. ZL200910087567. A method for separating and purifying mussel mucin using salting out and dialysis, and the like.

The mussel mucin used herein may be in the form of a solution or a lyophilized powder, in particular, the concentration of mussel mucin in the product may be 0.1-15.0 mg/ml, and when the concentration is too low, the effect of mussel mucin Not large, when the concentration is too high, it can cause cytotoxicity, skin irritation, etc., which is not conducive to the treatment of soft tissue inflammation.

The mussel mucin used herein can also be prepared as a liquid agent by combining it with an excipient. An exemplary mussel mucin liquid preparation is prepared by dissolving or diluting mussel mucin solution mother liquor or lyophilized powder to a certain concentration or pH, and the solution for dissolving or diluting may be water, physiological saline, phosphate solution, vinegar. Acid solution, borate solution, and the like. The pH of mussel mucin in the final product may be pH 1.0-7.0, and in particular, the therapeutic effect may be better in the range of pH 3.0-6.5.

The mussel mucin used herein can also be prepared as a gelling agent in combination with an excipient. An exemplary mussel mucin gel is prepared by mixing a mussel mucin solution or a lyophilized powder with a gel matrix material, which may be selected from the group consisting of cellulose derivatives, carbomers, and seaweeds. Acid salt, tragacanth, gelatin, pectin, carrageenan, gellan gum, starch, xanthan gum, cationic guar gum, agar, non-cellulosic polysaccharide, ethylene polymer, acrylic resin, polyvinyl alcohol or poly One of carboxyvinyl or any combination thereof.

One skilled in the art can select to use the above dosage forms or other suitable dosage forms depending on the characteristics of the clinical indications at different stages of the disease.

All of the above preparations can be prepared by methods well known in the art, and detailed procedures can be referred to, for example, "Pharmaceutics".

The mussel mucin used herein can be used as a main raw material to prepare a medicine using a pharmaceutically acceptable carrier. The drug may be a liquid agent or a gel. The drug may be administered by oral, spray, injection, targeted topical sustained release, targeted administration, and may be administered at a low temperature or in a heated manner.

The mussel mucin used herein can be used as a main raw material to prepare a medical device. The term medical device as used herein refers to materials that are used directly or indirectly to the human body and other similar or related items. The medical device may be a liquid agent, a gel, or a foaming agent. The medical device can It is used by oral administration, spraying, injection, targeted local sustained release, targeted administration, and can be administered at a low temperature or in a heated manner.

The mussel mucin used herein can be used as a main raw material, and a health care product or food can be prepared by using an excipient which is acceptable in the field of health care or food. The health care product or food may be a liquid agent or a gel. The health supplement or food may be administered by oral, spray, injection, targeted topical sustained release, targeted administration, and may be administered at a low temperature or in a heated manner.

Another object of the invention is to provide the use of mussel mucin products to inhibit soft tissue inflammation.

Surprisingly, the inventors have found that mussel mucin can alleviate various soft tissue inflammations such as muscles, ligaments, fascia, tendons, synovial membranes, fat, joint capsules, and contusions or lacerations of lymphoid tissues.

Musitis refers to chronic inflammation of muscles or tendons and attachments or tendon sheaths due to chronic damage, wind and cold dampness, infection, muscle spasms and other factors.

Ligamentitis is a chronic, non-red, non-swelling, non-fever, painful aseptic inflammatory injury. The treatment of ligamentitis is based on physiotherapy, supplemented by non-steroidal anti-inflammatory drugs such as fenbide.

Fasciitis is a non-specific inflammation that occurs in the myofascial fascia. Can occur in all parts of the body, more common in the waist, the posterior tibial and the scapular region. Non-steroidal anti-inflammatory drugs such as ibuprofen and diclofenac are commonly used drugs for the treatment of fasciitis.

Tendinitis refers to the degenerative pathological changes of tendon collagen fibers caused by excessive use of muscle fibers and repeated intense pulling. In addition to involving the tendon itself, it can also involve the tendon sheath. In most cases, it is often associated with the degeneration of collagen tissue in the affected tendon, so it is now known as tendinopathy. Tendinitis uses non-steroidal anti-inflammatory drugs to relieve pain, severe pain, and local injection of steroids. However, multiple injections of steroids weaken the strength of the tendon and cause the tendon to break.

Synovitis is a form of aseptic inflammation caused by joint sprains and multiple intra-articular injuries. Abnormal function of the synovial membrane can cause the joint fluid to fail to form and absorb normally, and the joint will produce fluid accumulation. The morphological changes of the synovial membrane can also invade the articular cartilage. If it is not treated in time, it will lead to osteoarthritis of the joints, and there is a disability crisis.

Lipitis is inflammation caused by damage to connective tissue between the lobule and the lobule composed of subcutaneous fat cells. The clinical manifestations lack specificity. The subcutaneous nodules or plaques are light red to tan, and the size and number are uncertain, and the pain and tenderness are conscious.

Joint capsule inflammation is an acute or chronic inflammation of the joint capsule. It is caused by direct violent injury, joint flexion, extension, abduction, external rotation, etc., caused by repeated, long-term, continuous friction and compression. disease. Clinical manifestations include pain, localized tenderness, limited mobility, and swelling. The treatment of joint capsule is treated with rest or affected part of the brakes and high-dose non-steroidal anti-inflammatory drugs, if necessary, anesthesia sedatives.

Lymphadenitis is a non-specific inflammation caused by acute and chronic inflammation involving lymph nodes in the drainage area of the lymph nodes. The infection of the upper limbs, breast, chest wall, back and ventral wall of the umbilicus causes axillary lymphadenitis; lower limbs, abdominal wall below the umbilicus, perineum Infections in the buttocks can occur in the inguinal lymphadenitis; infections in the head, face, mouth, neck and shoulders cause lymphadenitis in the submandibular and neck. Surprisingly, the inventors have discovered and confirmed that mussel mucin can be used to treat soft tissue inflammation caused by contusions or lacerations of muscles, ligaments, fascia, tendons, synovial membranes, fat, joint capsules, lymphoid tissues, and the like. The mussel mucin of the present invention can be used externally, directly acts on the affected part by transdermal absorption, and can also be absorbed to exert an anti-inflammatory pharmacological action. In addition, mussel mucin as a broad-spectrum anti-inflammatory agent does not cause damage to other tissues or organs.

DRAWINGS

Fig. 1 shows a mussel mucin liquid medicine of the present invention for use in treatment of muscle tissue inflammation, the upper graph being the day of treatment on day 0, and the lower panel being the result on day 21.

detailed description

Embodiments of the invention include:

1. The application of mussel mucin in the treatment of soft tissue inflammation.

2. The mussel mucin application according to embodiment 1, wherein the mussel mucin is from a subclass: mefp1, mefp-2, mefp-3, mefp-4, mefp-5, mefp-6, collagen pre a mixture of one or more of -COL-P, pre-COL-D, pre-COL-NG, foot silk matrix protein PTMP and DTMP.

3. The mussel mucin application according to embodiment 1, wherein the mussel mucin concentration may be from 0.1 to 15.0 mg/ml.

4. The mussel mucin application according to embodiment 1, wherein the mussel mucin is used as a liquid agent or a gel.

5. Mussel mucin application according to embodiment 1, wherein the mussel mucin in the final product may be in the range of pH 1.0-7.0, in particular in the range of pH 3.0-6.5.

The mussel mucin application according to any one of embodiments 1 to 5, wherein the soft tissue inflammation The disease can be selected from the group consisting of: muscle, ligament, fascia, tendon, synovium, fat, joint capsule, lymphoid tissue contusion or laceration caused by soft tissue inflammation.

7. Use of mussel mucin as an active ingredient in a composition for treating inflammation of a soft tissue, wherein the composition may be used as a liquid or gel.

8. The mussel mucin application according to embodiment 7, wherein the composition can be used by oral, spray, injection, targeted local sustained release, targeted administration.

9. Mussel mucin application according to embodiment 7, wherein the composition can be used at low temperature or in a heated manner.

10. A medicament for the treatment of soft tissue inflammation comprising mussel mucin and a pharmaceutically acceptable carrier, wherein the mussel mucin is present in a concentration of from 0.1 to 15.0 mg/ml.

11. A medical device for treating inflammation of a soft tissue comprising a mussel mucin and a carrier acceptable for use in the field of medical devices, wherein the concentration of mussel mucin may be from 0.1 to 15.0 mg/ml.

12. A health supplement/food for treating soft tissue inflammation, comprising mussel mucin and a health care product or a carrier acceptable for the food field, wherein the mussel mucin concentration may be from 0.1 to 15.0 mg/ml.

13. Use of mussel mucin in a medicament for treating inflammation of a soft tissue, wherein the soft tissue inflammation may be selected from the group consisting of muscles, ligaments, fascia, tendons, synovium, fat, joint capsule, and contusion or crack of lymphoid tissue. Soft tissue inflammation caused by injury.

14. The use of mussel mucin in a medical device for treating soft tissue inflammation, wherein the soft tissue inflammation can be selected from the group consisting of muscles, ligaments, fascia, tendons, synovium, fat, joint capsule, lymphoid tissue contusion or Soft tissue inflammation caused by laceration.

15. The use of mussel mucin in a health care product or food for treating soft tissue inflammation, wherein the soft tissue inflammation can be selected from the group consisting of: muscle, ligament, fascia, tendon, synovium, fat, joint capsule, lymphoid tissue. Soft tissue inflammation caused by contusion or laceration.

16. A method of treating inflammation of a soft tissue comprising formulating a mussel mucoid liquid or gel according to any one of the preceding embodiments 10-12 and administering to a subject in need thereof, wherein mussel mucin The concentration can be from 0.1 to 15.0 mg/ml.

17. The method of embodiment 16, wherein the soft tissue inflammation is selected from the group consisting of: muscle, ligament, fascia, tendon, synovial membrane, fat, joint capsule, contusion of a lymphoid tissue or soft tissue inflammation caused by a laceration.

The invention will now be further described in conjunction with specific embodiments. It should be noted that the pharmaceutical, medical device, health care product or food formed by various preparations of mussel mucin or mussel mucin in the present invention can be applied to the above as described above after administration to a subject. Indications and exhibiting the functions described above, all dosage forms within the scope of the invention have been tested, hereinafter, for illustrative purposes only a few of which are described in the examples, but should not be understood To limit the invention.

Unless otherwise stated, the reagents used in the present invention are commercially available.

Example 1: Application of mussel mucin gel drug in the treatment of leg muscle injury.

The mussel mucin solution was taken, mixed with guar gum and glycerol at a volume ratio of 2:1:1, and water was added thereto, and the pH was adjusted to 3.0 with citric acid to prepare a mussel mucoprotein content of 1.5 mg/ml. Shell mucin gel drug.

Ten patients with leg muscle injury diagnosed by orthopedic specialists were collected. The clinical manifestations of the selected cases were pain, swelling, tenderness or spasm. The selected cases were randomly assigned to the control group or the experimental group. The control group was treated with Yunnan Baiyao aerosol for 2 times a day. The dosage should be able to cover the affected area evenly. The test group used mussel mucin gel drug to spread the affected area. Second, the dosage should be able to cover the affected area evenly. There was no significant change in the control group after administration. The pain in the affected area was significantly weakened in the test group within 10-30 minutes. The visual analog VAS score decreased from 4.0-6.0 to 1.0-3.0 before treatment, and the analgesic time lasted for 2-5 hours. Also, as the use interval is extended, no dependence is exhibited.

After 7 days of continuous use, the pain and swelling symptoms of the injured part of the test group disappeared (Table 1), and the pain and swelling symptoms of the injured part of the control group disappeared after about 14 days. It can be seen that mussel mucin gel drugs can be used for the treatment of muscle damage, and the effect is better than traditional drugs.

Table 1:

Observation index Control group test group Average onset time (min) No relief 19.5±7.9 VAS average score before use 4,3±0.9 4.4±0.4 VAS average score after use 4,3±0.9 1.9±0.7 Average pain relief duration (h) No relief 3.2±1.0 Average recovery time (days) 12.9±3.2 5.7±0.8

Example 2: Application of mussel mucin liquid medical device in the treatment of ankle ligament injury.

A mussel mucin solution having a concentration of 0.5 mg/ml was prepared, diluted 5 times with 0.001% acetic acid, and the mussel mucin content was 0.1 mg/ml to obtain a mussel mucin liquid medical device.

Ten patients with ankle ligament laceration diagnosed by orthopedic specialists were collected. The clinical manifestations of the selected cases were pain, swelling, tenderness and subcutaneous hemorrhage (see the cyanosis area). The selected cases were randomly assigned to the control group or the experimental group. The control group was treated with Yunnan Baiyao aerosol for 3 times a day. The dosage should be able to cover the affected area evenly. The selected cases were sprayed with mussel mucin liquid medicine for 3 times a day. The dosage should be able to cover the affected area evenly. After the use, the pain in the control group was not relieved. The pain in the affected area was significantly weakened in the test group within 20-40 minutes. The visual analog VAS score was 4.0-6.0 before treatment to 1.0-3.0, and the analgesic time lasted 2-5 hours. Also, as the use interval is extended, no dependence is exhibited.

After 6 days of continuous spraying, the pain and swelling symptoms of the injured part disappeared in all subjects in the test group; after 12 days of continuous use, the pain and swelling symptoms of the injured part disappeared in all subjects in the control group (Table 2). It can be seen that the mussel mucin liquid medical device can be used for the treatment of ligament injury, and the effect is better than the traditional medicine.

Table 2:

Observation index Control group test group Average onset time (min) No relief 33.8±5.4 VAS average score before use 4.9±0.2 4.8±0.5 VAS average score after use 4.9±0.2 1.6±0.8 Average pain relief duration (h) No relief 4.0±0.7 Average recovery time (days) 10.6±0.8 4.9±1.0

Example 3: Application of mussel mucin liquid medicine in the treatment of fasciitis.

A mussel mucin solution having a concentration of 10.0 mg/ml was diluted with 0.01% citric acid to a mussel mucin content of 1.0 mg/ml to obtain a mussel mucin liquid medicine.

Two patients with lumbar fibrosis diagnosed by orthopedic specialists were collected. The clinical manifestations of the selected cases were persistent pain in the affected area. Ultrasound examination revealed obvious fissures in the fascia. Two patients were randomly assigned to the control group and the experimental group. Minimally invasive surgery was performed to remove the nodules, repair the fascia, separate the adhesions and remove the skin. After the passage, the control group was not treated, and the test group was locally injected with 0.5 ml of mussel mucin liquid medicine. After 1 week of treatment, the control group had mild pain symptoms, but the fascial fissures were still visible; the control group had no pain symptoms, and the fascial fissures had healed. It can be seen that mussel mucin liquid medicine can be used for the treatment of fasciitis.

Example 4: Application of mussel mucin gel medical device in the treatment of tendon injury.

Take 10g of hydroxypropyl methylcellulose, add 20ml of deionized water, warm bath at 90 °C for 30min to completely dissolve to obtain the gel matrix, and take another 2.5ml mussel mucin solution with a concentration of 10.0mg/ml, and add to the mixture while stirring. In the gel matrix, after mixing uniformly, a mussel mucin gel medical device was formed, wherein the mussel mucin concentration was 1.0 mg/ml.

Six patients with Achilles tendon injury diagnosed by orthopedic specialists were collected. The clinical manifestations of the selected cases were pain, swelling and tenderness. In the selected cases, the affected area was sprayed with mussel mucin gel medical device twice a day, and the dosage should be evenly covered. Pain in the affected area was significantly attenuated within 10-25 minutes after use, from a visual analog VAS score of 4.0-5.0 before treatment to 1.0-3.0, and an analgesic time of 2-5 hours. Also, as the use interval is extended, no dependence is exhibited.

After 1 week of continuous spraying, pain and swelling symptoms at the injury site disappeared in all subjects (Table 3). It can be seen that mussel mucin gel medical devices can be used for the treatment of Achilles tendon injuries.

table 3:

Observation index Average value Average onset time (min) 11.6±3.9 VAS average score before use 4.2±0.5 VAS average score after use 1.3±0.8 Average pain relief duration (h) 3.4±0.8 Average recovery time (days) 5.3±1.2

Example 5: Application of mussel mucin gel medical device in the treatment of knee joint synovitis.

Taking the mussel mucin solution, mixing with guar gum and glycerol at a mass ratio of 2:1:1, diluting with physiological saline, adjusting the pH to pH 5.0 with acetic acid to obtain a mussel mucin hydrogel medical device, wherein The mussel mucin concentration was 2.0 mg/ml.

Five patients with knee synovitis diagnosed by orthopedic specialists were collected. The clinical manifestations of the selected cases were Pain, swelling, and difficulty in movement. The selected cases were sprayed with mussel mucin hydrogel medical equipment twice a day, and the dosage should be able to cover the affected area evenly. After 1 week of continuous spraying, the pain and swelling symptoms of the injured part of all subjects disappeared. It can be seen that mussel mucin hydrogel medical devices can be used for the treatment of synovitis.

Example 6: Application of mussel mucin liquid medicine in the treatment of tonsillitis.

A mussel mucin solution having a concentration of 10.0 mg/ml was diluted with 0.01% citric acid to a mussel mucin content of 0.5 mg/ml to obtain a mussel mucin liquid medicine.

Ten patients with acute tonsillitis diagnosed by otolaryngologists were collected. The clinical manifestations of the patients were systemic fever and sore throat. The selected cases were randomly assigned to the control group or the experimental group. The control group was treated with oral penicillin twice a day. The test group was treated with mussel mucin liquid medicine and sprayed on the throat 3 times a day. . After 2 days of treatment, the fever symptoms of the control group disappeared and the sore throat was relieved; the fever symptoms disappeared and the sore throat was relieved in the test group. After 4 days of treatment, all the patients in the control group and the test group had normal body temperature and the symptoms of sore throat disappeared. It can be seen that mussel mucin liquid medicine can be used for the treatment of tonsillitis.

Example 7: Application of mussel mucin liquid medicine in the treatment of chronic refractory inflammatory wounds

The mussel mucin solution (MAP) was prepared by column chromatography with a protein concentration of 5.0 mg/ml and a purity of 90%. The above mussel mucin solution was taken and diluted with physiological saline to a mussel mucin content of 0.5 mg/ml to obtain a mussel mucin liquid medicine. Each 100 ml mussel mucin product contains mussel mucin 0.5 mg, sodium chloride 0.9 g, and the rest is water for injection.

Twelve patients with chronic refractory inflammatory wounds were collected and diagnosed as chronic wounds by surgical experts. The clinical manifestations of the patients were long-term unhealed wounds in the legs or feet of the patients. The depth of the ulcerated sites could reach the subdermal, muscular or bone surface.

The selected cases were randomly assigned to the control group or the experimental group. The control group was treated with the original succulent muscle cream (Jie Chuang, Wei Shi Tai Tang Tang Pharmaceutical) twice a day. The test group was treated with mussel mucin liquid medicine. 2 times a day. After 21 days of treatment, the chronic wounds of 6 patients in the control group showed no significant improvement. In the experimental group, 3 of the 6 patients basically healed, and the other 3 patients achieved a healing rate of more than 90%. Mussel mucin liquid medicine can be used for the treatment of chronic refractory inflammatory wounds and can be used to repair damaged muscle tissue.

Claims (10)

The application of mussel mucin in the treatment of soft tissue inflammation. The mussel mucin application according to claim 1, wherein said mussel mucin is from a subclass: mefp1, mefp-2, mefp-3, mefp-4, mefp-5, mefp-6, collagen pre-COL a mixture of one or more of -P, pre-COL-D, pre-COL-NG, foot silk matrix proteins PTMP and DTMP. The mussel mucin application according to claim 1, wherein the mussel mucin concentration is from 0.1 to 15.0 mg/ml. The mussel mucin application according to claim 1, wherein the mussel mucin is used as a liquid or gel. The mussel mucin application according to claim 1, wherein the mussel mucin in the final product is in the range of pH 1.0-7.0, particularly in the range of pH 3.0-6.5. The mussel mucin application according to any one of embodiments 1 to 5, wherein the soft tissue inflammation is selected from the group consisting of: muscle, ligament, fascia, tendon, synovium, fat, joint capsule, contusion or laceration of lymphoid tissue Soft tissue inflammation. Use of mussel mucin as an active ingredient in a composition for treating inflammation of a soft tissue, wherein the composition is used as a liquid or gel. Use of mussel mucin as an active ingredient in medicines for treating soft tissue inflammation. The use of mussel mucin as an active ingredient in medical devices for treating soft tissue inflammation. The use of mussel mucin as an active ingredient in health care products or foods for treating soft tissue inflammation.

Images